ActoGeniX (Belgium) a clinical-stage biopharmaceutical company focused on the development
of protein therapeutics for the treatment of gastrointestinal and metabolic diseases, closed a $17.1M Series B financing. Participants include Biovest, Gimv, Biotech Fund Flanders, Baekeland Fund, VIB, LSP, Aescap Venture and Ventech.